Literature DB >> 34339138

Longitudinal Serological Monitoring of Commercial Broiler Breeders for Fowl Adenoviruses (FAdVs)-Presence of Antibodies Is Linked with Virus Excretion.

Amin Mirzazadeh1,2, Beatrice Grafl2, Evelyn Berger2, Anna Schachner3, Michael Hess2,3.   

Abstract

Currently, the poultry industry worldwide is facing an emerging trend of fowl adenovirus (FAdV)-associated diseases with a significant economic impact, especially in meat-type chickens. Vertical transmission is an important feature of all FAdVs; hence, preventive measures mostly revolve around breeding stocks. However, knowledge about temporal development of FAdV infections in modern commercial settings is rare or even nonexistent. In the present study, longitudinal monitoring for FAdV was conducted in broiler breeder flocks located in a confined geographical region with intensive poultry production in Iran. For this, the antibody status of birds from 4 to 32 wk of age was monitored with a commercial FAdV-ELISA and virus neutralization test (VNT). In parallel, fecal shedding of FAdV was determined at the peak of egg production with real-time PCR and virus isolation. Overall, the commercial ELISA showed seroconversion of flocks before onset of production. VNT resolved in detail infection patterns of individual serotypes with a primordial FAdV-D (FAdV-2/-11) infection, frequently followed by FAdV-E (FAdV-8a, -8b) superinfection. FAdV-A (FAdV-1) was traced in half of the investigated flocks, while no evidence of infection with FAdV-C (FAdV-4, -10) was noted. Common serological profiles between different houses of the same farm indicate an overarching biosecurity. Serological profiles coupled with virological findings at the peak of egg production indicated that higher antibody levels, determined by ELISA, correlated with lower amounts of viral DNA in fecal excretion. Simultaneously, the number of isolated FAdVs belonging to distinct serotypes declined in accordance with a rise of neutralizing antibodies in birds, underlining the significance of serotype-specific antibodies in the epidemiology of FAdV in breeders. Investigations in breeders were complemented with screening of FAdV-associated diseases in local broilers over a 3-yr period; 26 cases of inclusion body hepatitis with dominant involvement of FAdV-11/FAdV-8b, one outbreak of adenoviral gizzard erosion related to FAdV-1, and no evidence of hepatitis-hydropericardium syndrome suggest that identical serotypes are maintained in the local poultry industry.

Entities:  

Keywords:  broiler breeder; fowl adenovirus; monitoring; serology; vertical transmission; virus excretion

Mesh:

Substances:

Year:  2021        PMID: 34339138     DOI: 10.1637/aviandiseases-D-20-00107

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.602


  4 in total

1.  Development of a Novel Avian Vaccine Vector Derived From the Emerging Fowl Adenovirus 4.

Authors:  Qing Pan; Yu Zhang; Aijing Liu; Hongyu Cui; Yulong Gao; Xiaole Qi; Changjun Liu; Yanping Zhang; Kai Li; Li Gao; Xiaomei Wang
Journal:  Front Microbiol       Date:  2021-12-01       Impact factor: 5.640

2.  High Phenotypic Variation between an In Vitro-Passaged Fowl Adenovirus Serotype 1 (FAdV-1) and Its Virulent Progenitor Strain despite Almost Complete Sequence Identity of the Whole Genomes.

Authors:  Beatrice Grafl; Anna Schachner; Michael Hess
Journal:  Viruses       Date:  2022-02-09       Impact factor: 5.048

3.  A 10-Year Retrospective Study of Inclusion Body Hepatitis in Meat-Type Chickens in Spain (2011-2021).

Authors:  Kateri Bertran; Angela Blanco; Noelia Antilles; Miquel Nofrarías; Rosa M Valle; Àlex Cobos; Antonio Ramis; Mar Biarnés; Natàlia Majó
Journal:  Viruses       Date:  2021-10-28       Impact factor: 5.048

4.  Isolation and Molecular Characterization of Fowl Adenovirus and Avian Reovirus from Breeder Chickens in Japan in 2019-2021.

Authors:  Makiko Yamaguchi; Yu Miyaoka; Md Amirul Hasan; Md Humayun Kabir; Dany Shoham; Harumi Murakami; Kazuaki Takehara
Journal:  J Vet Med Sci       Date:  2021-12-30       Impact factor: 1.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.